NCT07079735 - Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

January 17, 2028

Study Completion Date

January 17, 2029

Conditions

CMV ViremiaHeart Transplant InfectionHeart Transplant Failure and Rejection

Interventions

DRUG

Letermovir

CMV prophylaxis

DRUG

Valganciclovir

Standard therapy for CMV prophylaxis

Trial Locations (2)

RECRUITING

NYP-Weill Cornell, New York

RECRUITING

Columbia University/NYP Milstein Hospital, New York